natgillin/translations-raw huggingface dataset:
Ibandronic acid 3 mg intravenous injection, administered every 3 months, was shown to be at least as effective as oral ibandronic acid 2.5 mg daily in a 2-year, randomised, double-blind, multicentre, non- inferiority study (BM16550) of postmenopausal women (1386 women aged 55 - 80) with osteoporosis (lumbar spine BMD T-score below -2.5 SD at baseline).
Ibandronska kislina v obliki 3-mg intravenske injekcije, ki se daje vsake 3 mesece, se je izkazalo za najmanj enako učinkovito kakor ibandronska kislina 2,5 mg enkrat na dan peroralno v dveletni randomizirani, dvojno slepi, multicentrični, neinferiorni študiji (BM 16550) pri ženskah z osteoporozo v postmenopavzi (1.386 žensk, starih 55 do 80 let z izhodiščno T-vrednostjo MKG ledvene hrbtenice pod –2,5 SD).
Ibandronic acid 50 mg n=287
ibandronska kislina 50 mg
Ibandronic acid 6 mg n=154
Ibandronska kislina 6 mg
Ibandronic acid Accord 2 mg and 6 mg concentrate for solution for infusion (for oncology indications):
Ibandronska kislina Accord 2 mg in 6 mg koncentrat za raztopino za infundiranje (za onkološke indikacije):
Ibandronic acid Accord 2 mg concentrate for solution for infusion
Ibandronska kislina Accord 2 mg koncentrat za raztopino za infundiranje
Ibandronic acid Accord 3 mg solution for injection in pre-filled syringe
Ibandronska kislina Accord 3 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
Ibandronic acid Accord 3 mg solution for injection in pre-filled syringe Ibandronic acid
Ibandronska kislina Accord 3 mg raztopina za injiciranje v napolnjeni injekcijski brizgi ibandronska kislina
Ibandronic acid Accord 3 mg solution for injection in pre-filled syringe should be injected intravenously over a period of 15 - 30 seconds.
Ibandronska kislina Accord 3 mg raztopina za injiciranje v napolnjeni injekcijski brizgi se daje intravensko 15 do 30 sekund.
Ibandronic acid Accord 3 mg solution for injection in pre-filled syringes is a clear colourless solution.
Ibandronska kislina Accord 3 mg raztopina za injiciranje v napolnjeni injekcijski brizgi je bistra, brezbarvna raztopina.
Ibandronic acid Accord 3 mg solutionfor injection (for osteoporosos indications): Medicinal product subject to medical prescription.
Ibandronska kislina Accord 3 mg raztopina za injiciranje (za indikacije, povezane z osteoporozo): Predpisovanje in izdaja zdravila je le na recept.
Ibandronic acid Accord 6 mg concentrate for solution for infusion
Ibandronska kislina Accord 6 mg koncentrat za raztopino za infundiranje
Ibandronic acid Accord concentrate for solution for infusion should be administered as an intravenous infusion.
Koncentrat za raztopino za infundiranje Ibandronska kislina Accord damo kot intravensko infuzijo.
Ibandronic acid Accord contains less than 1 mmol sodium (23 mg) per dose (3 ml), i.e. essentially “sodium-free”.
Zdravilo Ibandronska kislina Accord vsebuje manj kot 1 mmol (23 mg) natrija na odmerek (3 ml), kar v bistvu pomeni ‛brez natrija’.
Ibandronic Acid Accord contains less than 1 mmol sodium (23 mg) per vial, i.e. ‘essentially sodium free’.
Zdravilo Ibandronska kislina Accord vsebuje manj kot 1 mmol natrija (23 mg) na vialo, kar v bistvu pomeni "brez natrija".
Ibandronic acid Accord is a colourless, clear solution.
Zdravilo Ibandronska kislina Accord je brezbarvna, bistra raztopina.
Ibandronic acid Accord is used in adults and prescribed to you if you have breast cancer that has spread to your bones (called ‘bone metastases’).
Zdravilo Ibandronska kislina Accord uporabljamo pri odraslih in vam ga bodo predpisali, če imate raka dojke, ki se je razširil na kosti (metastaze v kosteh).
Ibandronic acid Accord is usually administered in a hospital setting.
Dajanje zdravila Ibandronska kislina Accord običajno poteka v bolnišnici.
Ibandronic acid Accord must not be used in children or adolescents below 18 years.
Zdravila Ibandronska kislina Accord se ne sme uporabljati pri otrocih ali mladostnikih, mlajših od 18 let.
Ibandronic acid Accord should not be used in children and adolescents below the age of 18 years.
Zdravilo Ibandronska kislina Accord se ne sme uporabljati pri otrocih in mladostnikih starih manj kot 18 let.
Ibandronic acid injection is essentially sodium free.
Zdravilo Ibandronska kislina Accord je praktično brez natrija.
Ibandronic acid is eliminated by renal excretion only and does not undergo any biotransformation.
Ibandronska kislina se izloča le z renalno ekskrecijo in ni podvržena biotransformaciji. .
Ibandronic acid is removed from the circulation via bone absorption (estimated to be 40 – 50 % in postmenopausal women) and the remainder is eliminated unchanged by the kidney.
Ibandronska kislina se odstrani iz obtoka s kostno absorpcijo (ocenjeno na 40 do 50 % pri ženskah v postmenopavzi), ostanek pa se izloči skozi ledvice v nespremenjeni obliki.
Ibandronic acid Sandoz 50 mg
Ibandronska kislina Sandoz 50 mg
Ibandronic acid Sandoz 50 mg film-coated tablets
Ibandronska kislina Sandoz 50 mg filmsko obložene tablete
Ibandronic acid Sandoz 50 mg film-coated tablets are supplied in Polyamide/Al/PVC - Aluminium foil blister with 3, 6, 9, 28 or 84 tablets, packaged in a cardboard box.
Filmsko obložene tablete Ibandronska kislina Sandoz 50 mg so na voljo v škatlah s pretisnimi omoti (poliamid/Al/PVC – aluminijasta folija) po 3, 6, 9, 28 ali 84 tablet.
Ibandronic acid Sandoz contains lactose
Zdravilo Ibandronska kislina Sandoz vsebuje laktozo
Ibandronic Acid Sandoz is a ‘generic medicine’.
Ibandronic Acid Sandoz je „generično zdravilo“.
Ibandronic Acid Sandoz is used to prevent ‘skeletal events’ (fractures [broken bones] or bone complications requiring treatment) in patients with breast cancer and bone metastases (when the cancer has spread to the bone).
Zdravilo Ibandronic Acid Sandoz se uporablja za preprečevanje z okostjem povezanih dogodkov (zlomov kosti ali z okostjem povezanih zapletov, ki zahtevajo zdravljenje) pri bolnikih z rakom dojke in metastazami v kosteh (ko se je rak razširil v kosti).
Ibandronic acid Sandoz should not be used in children and adolescents below the age of 18 years.
Zdravila Ibandronska kislina Sandoz ne smemo uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
Ibandronic acid Sandoz with food and drink
Zdravilo Ibandronska kislina Sandoz skupaj s hrano in pijačo
Ibandronic acid should not be used during breast-feeding.
Ibandronske kisline se ne sme uporabljati med dojenjem.
Ibandronic acid should not be used during breastfeeding.
Ibandronske kisline se med dojenjem ne sme uporabljati.
Ibandronic Acid Teva
Ibandronska kislina Teva
Ibandronic Acid Teva 150 mg film-coated tablets
Ibandronska kislina Teva 150 mg filmsko obložene tablete
Ibandronic Acid Teva 150 mg film-coated tablets
Ibandronska kislinaTeva 150 mg filmsko obložene tablete
Ibandronic Acid Teva 150 mg film-coated tablets ibandronic acid
Ibandronska kislina Teva 150 mg filmsko obložene tablete ibandronska kislina
Ibandronic Acid Teva 50 mg film-coated tablets
Ibandronska kislina Teva 50 mg filmsko obložene tablete
Ibandronic Acid Teva 50 mg is used to prevent ‘skeletal events’ (fractures [broken bones] or bone complications requiring treatment) in patients with breast cancer and bone metastases (when the cancer has spread to the bone).
Zdravilo Ibandronic Acid Teva se uporablja za preprečevanje z okostjem povezanih dogodkov (zlomov kosti ali z okostjem povezanih zapletov, ki zahtevajo zdravljenje) pri bolnicah z rakom dojke in kostnimi metastazami (ko se rak razširi na kosti).
Ibandronic Acid Teva 50 mg: Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).
Ibandronska kislina Teva 50 mg: Predpisovanje in izdaja zdravila je pod omejenimi pogoji in na recept (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
Ibandronic Acid Teva belongs to a group of medicines called bisphosphonates.
Ibandronska kislina Teva spada v skupino zdravil, ki jih imenujemo difosfonati.
Ibandronic Acid Teva comes in blisters (PVC/Aclar/PVC – Aluminium) in cartons of 1 or 3 tablets.
Zdravilo Ibandronska kislina Teva je na voljo v pretisnih omotih (PVC/Aclar/PVC in aluminij) v kartonskih škatlah, ki vsebujejo 1 ali 3 tablete.
Ibandronic Acid Teva comes in blisters (PVC/Aclar/PVC – Aluminium) in cartons of 28 or 84 tablets.
Zdravilo Ibandronska kislina Teva je na voljo v pretisnih omotih (PVC/Aclar/PVC in aluminij) v kartonskih škatlah, ki vsebujejo 28 ali 84 tablet.
Ibandronic Acid Teva is a ‘generic medicine’.
Ibandronic Acid Teva je generično zdravilo.
Ibandronic Acid Teva is less effective if it’s taken with food.
Zdravilo Ibandronska kislina Teva je manj učinkovito, če ga vzamete s hrano.
Ibandronic Acid Teva may also do so.
To velja tudi za zdravilo Ibandronska kislina Teva.
Ibandronic Acid Teva should not be used during lactation.
Zdravilo Ibandronska kislina Teva se ne sme uporabljati med dojenjem.
Ibandronic Acid Teva should not be used in children and adolescents below the age of 18 years.
Zdravilo Ibandronska kislina Teva se ne sme uporabljati pri otrocih in mladostnikih, starih manj kot 18 let.
Ibandronic Acid Teva with food and drink
Zdravilo Ibandronska kislina Teva skupaj s hrano in pijačo
Ibandronic acid therapy should only be initiated by physicians experienced in the treatment of cancer.
Zdravljenje z ibandronsko kislino lahko vpelje le zdravnik z izkušnjami pri zdravljenju raka.
Iblias contains sodium
Iblias inniheldur natríum
Iblias does not contain von Willebrand factor.
Iblias inniheldur ekki von Willebrand storkuþátt.
Ibraxion contains a gene deleted IBR virus, which is inactivated.
Zdravilo Ibraxion vsebuje inaktiviran IBR virus z izbrisanim genom.
Ibraxion contains mineral oil.
Zdravilo Ibraxion vsebuje mineralno olje.
Ibraxion has been studied using the recommended dosing in all categories and age groups of animals.
Zdravilo Ibraxion so raziskovali z uporabo priporočenih odmerkov pri vseh kategorijah in starostnih skupinah živali.
Ibraxion is also intended to reduce the spread of the IBR virus by reducing the amount of virus excreted by the animals.
Zdravilo Ibraxion je namenjeno tudi zmanjševanju razširjanja IBR virusa, ker zmanjšuje količino virusa, ki ga izločajo živali.
Ibraxion is an emulsion for injection.
Zdravilo Ibraxion je emulzija za injiciranje.
Ibraxion is shaken before use and injected subcutaneously (under the skin) into the neck at the front of the shoulder.
Zdravilo Ibraxion je treba pred uporabo pretresti in ga nato subkutano (pod kožo) injicirati v predel vratu na prednjem delu rame.
Ibraxion is used to immunise cattle to reduce the clinical signs of IBR and reduce field virus excretion (virus that is passed out of the animal).
Ibraxion se uporablja za imuniziranje goveda, da bi s tem zmanjšali klinične znake IBR in zmanjšali izločanje virusa na terenu (virus, ki so ga izločile živali).
Ibraxion may cause a slight rise in body temperature (less than 1°C) for less than 48 hours after injection.
Zdravilo Ibraxion lahko povzroči blago povečanje telesne temperature (manj kot 1 C) za manj kot 48 ur po injiciranju.
Ibritumomab tiuxetan is a recombinant murine IgG1 kappa monoclonal antibody specific for the B- cell antigen CD20.
Ibritumomab tiuksetan je kappa monoklonsko protitelo na osnovi rekombinantnega mišjega IgG1, ki je specifično za B-celični antigen CD20.
ibritumomab tiuxetan vial: sodium chloride, water for injections
viala z ibritumomab tiuksetanom: natrijev klorid, voda za injekcije
Ibrutinib has minimal renal clearance; urinary excretion of metabolites is < 10% of the dose.
Ibrutinib se le v majhni meri izloča skozi ledvice; izločanje presnovkov z urinom predstavlja manj kot 10% danega odmerka.
Ibrutinib is a P-gp and breast cancer resistance protein (BCRP) inhibitor in vitro.
In vitro ibrutinib zavira P-glikoprotein in protein pri odpornosti za raka dojke (BCRP-breast cancer resistance protein).
Ibrutinib is a potent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK).
Ibrutinib je majhna molekula z močnim zaviralnim delovanjem na Brutonovo tirozinsko kinazo (BTK).
Ibrutinib may also inhibit BCRP in the liver and increase the exposure of drugs that undergo BCRP-mediated hepatic efflux, such as rosuvastatin.
Ibrutinib lahko zavira tudi BCRP v jetrih in zveča izpostavljenost zdravilom, katerih izločanje skozi jetra je povezano z BCRP, kot je rosuvastatin.
Ibuprofen
Navodilo shranite.
ibuprofen ( used to treat fever, pain and some forms of inflamamtion),
ibuprofen (uporablja se za zdravljenje povišane telesne temperature, bolečine in nekaterih oblik vnetja),
Ibuprofen is a non selective inhibitor of cyclo- oxygenase, leading to reduced synthesis of prostaglandins.
Ibuprofen je neselektivni inhibitor ciklooksigenaze, kar zmanjšuje sintezo prostaglandinov.
Ibuprofen may reduce the ability of your baby’s blood to clot.
Ibuprofen lahko zmanjša sposobnost strjevanja krvi vašega otroka.
ibuprofen, diclofenac, ketorolac or other medicines - used to treat pain and swelling in arthritis and other illnesses
ibuprofen, diklofenak, ketorolak ali druga podobna zdravila – ki se uporabljajo za lajšanje bolečine in vnetja pri artritisu ter drugih boleznih,
Ibutilide Sotalol (saquinavir/ritonavir)
ibutilid sotalol (sakvinavir/ritonavir)
ic vasculitis
čni vaskulitis
Icandra 50 mg/850 mg film-coated tablets are yellow, oval tablets with “NVR” on one side and “SEH” on the other.
Icandra 50 mg/850 mg filmsko obložene tablete so rumene, ovalne tablete z oznako “NVR” na eni strani in “SEH” na drugi.
Icandra is available in packs containing 10, 30, 60, 120, 180 or 360 film-coated tablets and in multi- packs containing 120 (2x60), 180 (3x60) or 360 (6x60) film-coated tablets.
Zdravilo Icandra je na voljo v pakiranjih po 10, 30, 60, 120, 180 ali 360 filmsko obloženih tablet in v skupnih pakiranjih, ki vsebujejo po 120 (2x60), 180 (3x60) ali 360 (6x60) filmsko obloženih tablet.
Icandra is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea.
Zdravilo Icandra je indicirano v kombinaciji s sulfonilureo (torej kot del zdravljenja s trojno kombinacijo zdravil) poleg diete in telesne dejavnosti pri odraslih bolnikih, pri katerih diabetesa ni mogoče ustrezno urediti samo z metforminom in sulfonilureo.
Icandra is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.
Zdravilo Icandra je indicirano za zdravljenje odraslih bolnikov, pri katerih diabetesa ni mogoče urediti samo z metforminom v največjem peroralnem odmerku, ki ga še prenašajo, ali pri tistih, ki že prejemajo zdravljenje z vildagliptinom in metforminom v obliki ločenih tablet.
Icandra is indicated in the treatment of type 2 diabetes mellitus:
Zdravilo Icandra je indicirano za zdravljenje bolnikov z diabetesom tipa 2:
Icandra is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
Zdravilo Icandra je indicirano kot del zdravljenja s trojno kombinacijo z insulinom poleg diete in telesne dejavnosti pri odraslih bolnikih, pri katerih diabetesa ni mogoče ustrezno urediti samo z metforminom in insulinom v stabilnem odmerku.
Icandra may be initiated at either the 50 mg/850 mg or 50 mg/1000 mg tablet strength twice daily, one tablet in the morning and the other in the evening.
Zdravljenje z zdravilom Icandra je mogoče začeti z uporabo tablet bodisi jakosti 50 mg/850 mg ali 50 mg/1000 mg dvakrat dnevno in sicer eno tableto zjutraj, drugo pa zvečer.
Icandra should not be used during pregnancy.
Zdravila Icandra se ne sme uporabljati med nosečnostjo.
Icandra should not be used in patients with creatinine clearance < 60 ml/min (see sections 4.3, 4.4 and 5.2).
Bolniki z očistkom kreatinina < 60 ml/min ne smejo uporabljati zdravila Icandra (glejte poglavja 4.3, 4.4 in 5.2).
Icatibant
ikatibant
Icatibant is extensively metabolized by proteolytic enzymes to inactive metabolites that are primarily excreted in the urine.
Ikatibant obsežno presnavljajo proteolitični encimi v neaktivne presnovke, ki se primarno izločajo z urinom.
Icatibant was not teratogenic when administered by s.c. injection during early embryonic and fetal development in rat (top dose 25 mg/kg/day) and rabbit (top dose 10 mg/kg/day).
Ikatibant ni bil teratogen, ko so ga dajali s subkutano injekcijo med zgodnjim embrionalnim in fetalnim razvojem pri podganah (maksimalni odmerek 25 mg/kg/dan) in zajcih (maksimalni odmerek 10 mg/kg/dan).
icca syndrome (including dry eyes and dry mouth)
Sjögrenov sindrom (vključno s suhimi očmi in suhimi usti)
icca syndrome (including dry eyes and dry mouth);
Sjögrenov sindrom (vključno s suhimi očmi in suhimi usti);
Ice may be applied to the affected area for approximately 30 minutes.
Na prizadeto mesto lahko za približno 30 minut položite led.
Ice will be put on the affected area for 30 minutes.
Na prizadeto področje je treba za 30 minut položiti led.
Iceland/ Ísland Cardiome UK Limited Sími: +41 848 00 79 70
Iskandija/Ísland Cardiome UK Limited Sími: +41 848 00 79 70
ICH non-fatal
ICH ne-fatalna
icinal icinal
ilo ilo
ickle cell anaemia (an abnormality of red blood cells).
rpastocelično anemijo (nenormalnost rdečih krvničk).
ickle cell anaemia;
anemijo srpastih celic,
ickle cell anaemia;
anemijo srpastih celic;
ickness (mild nausea) feeling of pins and needles (mild peripheral neuropathy)
iljenje na bruhanje (blaga slabost), mravljinčenje (blaga periferna nevropatija).
ickness,
istema
ickness,
labost,
Iclusig 15 mg film-coated tablets ponatinib
Iclusig 15 mg filmsko obložene tablete ponatinib
Iclusig 30 mg film-coated tablets ponatinib
Iclusig 30 mg filmsko obložene tablete ponatinib
Iclusig 45 mg film-coated tablets ponatinib
Iclusig 45 mg filmsko obložene tablete ponatinib
Iclusig can lead to clots or blockages in arteries and veins and patients should have the condition of their heart and circulation considered before starting and during treatment, and be treated appropriately for any problems.
Zdravilo Iclusig lahko povzroči nastanek strdkov ali zapor v arterijah in venah, zato je treba oceniti stanje bolnikovega srca in ožilja pred ali med zdravljenjem ter morebitne težave ustrezno rešiti.
Iclusig can only be obtained with a prescription and treatment should be started by a doctor who is experienced in the diagnosis and treatment of leukaemia.
Izdaja zdravila Iclusig je le na recept, zdravljenje pa lahko uvede zdravnik z izkušnjami z diagnosticiranjem in zdravljenjem bolnikov z levkemijo.
Iclusig contains lactose
Zdravilo Iclusig vsebuje laktozo
Iclusig has been investigated in one main study involving 449 patients with CML or Ph+ ALL and who were intolerant or resistant to treatment with dasatinib or nilotinib, or had the T315I mutation.
Zdravilo Iclusig so proučevali v eni glavni študiji s 449 bolniki s KML ali Ph+ ALL, ki niso prenašali zdravljenja z dasatinibom ali nilotinibom oziroma so bili odporni nanju ali so imeli mutacijo T315I.
Iclusig is a cancer medicine that contains the active substance ponatinib.
Iclusig je zdravilo za zdravljenje raka, ki vsebuje zdravilno učinkovino ponatinib.
Iclusig is available as tablets (15 mg, 30 mg and 45 mg).
Zdravilo Iclusig je na voljo v obliki tablet (15 mg, 30 mg in 45 mg).
Iclusig is used in patients who cannot tolerate or do not respond to dasatinib or (for patients with CML) nilotinib, which are other cancer medicines of the same class, and in whom subsequent treatment with imatinib (a third such medicine) is not considered appropriate.
Zdravilo Iclusig se uporablja pri bolnikih, ki ne prenašajo oziroma se ne odzivajo na dasantib ali (za bolnike s KML) nilotinib, ki sta drugi zdravili proti raku istega razreda, ter pri bolnikih, pri katerih nadaljnje zdravljenje z imatinibom ni primerno.
Iclusig should be interrupted immediately in case of vascular occlusion.
Zdravljenje z zdravilom Iclusig takoj prekiniti, če se pojavi žilna okluzija.
Iclusig with food and drink
Zdravilo Iclusig skupaj s hrano in pijačo
IDA 8 mg/m2 i.v. (0.5 h), days 7, 8, 14, 15; CP 500 mg/m2 i.v.(1 h) day 1;
IDA 8 mg/m2 i.v. (0,5 ure), 7., 8., 14., 15. dan; CP 500 mg/m2 i.v.(1 ura) 1. dan;
IDA 8 mg/m2 i.v. (0.5 h), days 7, 8, 14, 15; CP 500 mg/m2 i.v.(1 h) day 1;
IDA 8 mg/m² i.v. (0,5 ur), 7., 8., 14., 15. dan; CP 500 mg/m² i.v.(1 ura) 1. dan;
IDA 9 mg/m2 oral, days 1-28;
IDA 9 mg/m2 peroralno, 1.-28. dan;
IDA 9 mg/m2 oral, days 1-28;
IDA 9 mg/m² peroralno, 1.-28. dan;
IDA Business & Technology Park Carrigtohill, County Cork
IDA Business & Technology Park Carrigtohill,County Cork
ide effects caused by the other medicines you are also taking complications of HIV infection.
neželenimi učinki, ki jih povzročajo druga zdravila, ki jih jemljete, zapleti okužbe s HIV.
ide effects caused by the other medicines your child is also taking complications of HIV infection.
neželenimi učinki, ki jih povzročajo druga zdravila, ki jih jemlje vaš otrok; zapleti okužbe s HIV.
ideation, suicide
o samomoru, poizkus
Idebenone is used to treat vision impairment in adults and adolescents with an eye disease called Leber’s Hereditary Optic Neuropathy (LHON).
Idebenon se uporablja za zdravljenje poslabšanja vida pri odraslih in mladostnikih z očesno boleznijo, imenovano Lebrova dedna optična nevropatija (LHON).
Idebenone may inhibit P-glycoprotein (p-gp) with possible exposure increases of e.g. dabigatran etexilate, digoxin or aliskiren.
Idebenon lahko zavira P-glikoprotein (p-gp) z morebitnim povečanjem izpostavljenosti npr. dabigatraneteksilatu, digoksinu ali aliskirenu.
IDegLira obs. rate IDegLira
IDegLira op. delež IDegLira
IDegLira=Xultophy, IDeg=insulin degludec, Lira=liraglutide, obs. rate=observed rate, PYE=patient year of exposure
IDegLira = zdravilo Xultophy, IDeg = insulin degludek, Lira = liraglutid, op. delež = opaženi delež, PYE = bolnikov-let izpostavljenosti (patient year of exposure)
Idelalisib + O
Idelalizib + O
Idelalisib + O N = 174
Idelalizib + O N = 174
Idelalisib + R
Idelalizib + R
Idelalisib + R 110 (0) 101 (3) 93 (7) 73 (9) 59 (14) 31 (19) 20 (21) 9 (24) 7 (24) 4 (24) 1 (25) 0 (25)
Idelalizib + R 110 (0) 101 (3) 93 (7) 73 (9) 59 (14) 31 (19) 20 (21) 9 (24) 7 (24) 4 (24) 1 (25) 0 (25)
Idelalisib + R N = 110
Idelalizib + R N = 110
Idelalisib exposure may be reduced when co-administered with CYP3A inducers such as rifampicin, phenytoin, St. John’s wort (Hypericum perforatum), or carbamazepine.
Izpostavljenost idelalizibu se lahko zmanjša pri sočasni uporabi z induktorji CYP3A, kot so rifampicin, fenitoin, šentjanževka (Hypericum perforatum) ali karbamazepin.
Idelalisib is a selective inhibitor of adenosine-5’-triphosphate (ATP) binding to the catalytic domain of PI3Kδ, resulting in inhibition of the phosphorylation of the key lipid second messenger phosphatidylinositol and prevention of Akt (protein kinase B) phosphorylation.
Idelalizib je selektivni zaviralec adenozin 5’-trifosfata (ATP), ki se veže na katalitično domeno PI3Kδ, kar povzroči zaviranje fosforilacije fosfatidilinozitola, glavnega lipidnega sekundarnega obveščevalca, in prepreči fosforilacijo Akt (proteinske kinaze B).
Idelalisib should not be co-administered with alfuzosin.
Idelaliziba se ne sme dati sočasno z alfuzosinom.
Idelalisib should not be co-administered with cisapride.
Idelaliziba se ne sme dati sočasno s cisapridom.
Idelalisib should not be co-administered with ergotamine or dihydroergotamine.
Idelaliziba se ne sme dati sočasno z ergotaminom ali dihidroergotaminom.
Idelalisib should not be co-administered with quetiapine or pimozide.
Idelaliziba se ne sme dati sočasno s kvetiapinom ali pimozidom.
IDELVION 1000 IU powder and solvent for solution for injection 260 – 300 mOsm/kg.
IDELVION 1000 i.e. prašek in vehikel za raztopino za injiciranje 260 – 300 mOsm/kg
IDELVION 1000 IU powder and solvent for solution for injection 3 years
IDELVION 1000 i.e. prašek in vehikel za raztopino za injiciranje 3 leta
IDELVION 2000 IU powder and solvent for solution for injection 260 – 300 mOsm/kg.
IDELVION 2000 i.e. prašek in vehikel za raztopino za injiciranje 260 – 300 mOsm/kg